Tuesday, June 18, 2019
News
NEWS HOME
»
PRESS RELEASES

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1
  SocialTwist Tell-a-Friend  
   


Date: 21-05-2019 12:28PM
Source: Boehringer Ingelheim
Category: General, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: Ingelheim, Germany

Business Wire India

  • Results of pivotal Phase III SENSCIS® trial published today in the New England Journal of Medicine(NEJM) and presented at the American Thoracic Society Conference in Dallas, USA
  • Interstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) – also known as scleroderma – and the absence of approved treatment options constitutes a high unmet need2,3
  • FDA grants priority review to application for regulatory approval for nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD)


Boehringer Ingelheim today announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVCa) in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD). Results show thatnintedanib slows the loss of pulmonary function in patients with SSc-ILD compared to placebo. Patients taking nintedanib showed a 44% reduction in the rate of decline of their lung function, measured in FVC assessed over 52 weeks1. These new data were today published in the New England Journal of Medicine (NEJM) and presented to the medical community at the American Thoracic Society (ATS) International Conference, in Dallas, USA.

SENSCIS® is the largest randomised controlled trial to be conducted in patients with SSc-ILD, a disease for which there are currently no approved treatments.1,3,4 Results also showed that nintedanib had a safety and tolerability profile similar to that observed in patients with idiopathic pulmonary fibrosis (IPF)1, with the most common adverse event being diarrhoea. Nintedanib is already approved in more than 70 countries for the treatment of IPF. These trial results formed the basis of the application for regulatory approval of nintedanib in SSc-ILD that was filed with the FDA and EMA by Boehringer Ingelheim in the first quarter of 2019. The FDA recently granted priority review to the supplemental application for nintedanib in SSc-ILD. The regulatory submissions are part of the company’s ongoing commitment to improving the lives of people living with pulmonary fibrosis, in particular those affected by rare diseases with a high level of unmet need.

Systemic sclerosis, also known as scleroderma, is a rare incurable autoimmune disease affecting connective tissue.3,4,5 It can cause scarring (fibrosis) of the skin as well as major organs such as the heart, lungs, digestive tract and kidneys and can have life-threatening complications.2,3 Approximately 25 percent of patients develop significant pulmonary involvement within three years of diagnosis.6 When SSc affects the lungs it can cause interstitial lung disease (ILD), known as SSc-ILD.2,3 It is a key driver of mortality among people with SSc, accounting for approximately one third of deaths.7,8

SENSCIS®, a Phase III double-blind, randomised, placebo-controlled trial, involved 576 patients across more than 32 countries. The primary endpoint was the annual rate of decline in FVC in mL over 52 weeks.1 At the end of the 52-week trial, patients receiving nintedanib had an adjusted annual rate of decline in FVC (mL/year) of -52.4 with nintedanib, versus -93.3 with placebo (absolute difference 41.0mL/year [95% CI 2.9, 79.0]; p=0.04). This corresponds to a relative difference of 44% reduction in lung function decline1,similar to the results from the Phase III INPULSIS® trials in IPF.12 FVC is an established measurement of lung function. As ILD progresses, lung function gradually and irreversibly deteriorates.9

“The SENSCIS results provide positive news for people living with SSc-ILD and their physicians because currently there are no approved treatments” explained Professor Oliver Distler, Professor of Rheumatology, University Hospital Zurich and lead investigator of the trial. “A 44% reduction in lung function decline indicates a significant slowdown in disease progression. Nintedanib could make a considerable difference to the lives of people with this rare and often life-threatening disease.”

“We are pleased to be able to share the positive results of the pivotal SENSCIS trial that are very consistent with the database from IPF and formed the basis of the recent submissions Boehringer Ingelheim made to the FDA and EMA for regulatory approval of nintedanib in February and March 2019”, said Dr. Susanne Stowasser, Associate Head of Medicine, Respiratory at Boehringer Ingelheim. “Fibrotic lung diseases including SSc-ILD continue to have a devastating impact on people’s lives and our focus remains on making treatments available to improve the lives of patients in areas of high unmet need.”

~ENDS~

Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/nintedanib-slows-pulmonary-function-loss-in-people-with-ssc-ild



CONTACTS :

Boehringer Ingelheim
Corporate Communications
Media + PR
Alexander Kurz
55216 Ingelheim/Germany
Tel.: +49 (6132) 77-184531
Mobile: +49 (151) 68948378
Email: press@boehringer-ingelheim.com

More Press Releases

Intertrust Acquires Viteos for USD 330 Million

SES Networks Enables EMSA’s Environmental Protection Service in Iceland

Rakuten Social Accelerator to Launch in India

Viaan Industries Ltd - a Raj Kundra Promoted Company, Partners With Indian Cyber Security Whizkid Manan Shah

Tackle Any Financial Emergency With an Instant Personal Loan by Bajaj Finserv

Animation, Sound & Vibration – How Visa is Reinforcing Consumer Trust in a Changing Payments World

MagicStay Raises €3 Million to Accelerate Its International Development

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPa Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

@cosme Announces "THE BEST COSMETICS AWARDS 2019 Mid-Year New Products";"FACE POWDER" from COSME DECORTÉ Wins Grand Prize!

EPLAN Chooses Thales to Enable Cloud-Based Licensing, Addressing Growing Business Needs

Toshiba Memory Holdings Reorganizes Its Capital Structure

Internationally Renowned Oncologist, Dr. Anil K. D’Cruz is Now Associated With Apollo Hospitals as Director, Oncology

WarnerMedia Innovation Lab Continues to Lean into Future Tech with Several Key Announcements

SPH, NTUC Income and LumenLab Leverage Blockchain to Automate the Verification Process for Life Insurance Claims for Bereaved Families

Study from Project Management Institute Identifies Six AI Technologies Impacting Project Professionals

Panasonic Signs Joint Business Development Agreement with Startup Linkwiz to Enhance Welding Processes in Manufacturing

Philip Morris International Holds ‘Open Mic’ at 2019 Cannes Lions Festival

WNS to Sponsor 2019 Travelers Championship

WPP and iHeartMedia Launch ‘Project Listen’

Frost & Sullivan and TERI’s 2019 India Sustainability Leadership Summit Sought Means to Establish a Circular Economy that Embraces Solutions with Potential to transform our Future

Infor Announces New India Business Unit to Accelerate Strategic Growth and Increase Customer Intimacy

MAHE Signs Three Agreements With University of Lille

Good Call: Vodafone Joins SeeHer

L&T Technology Services Successfully Concludes its Engineering The Change Campaign in Europe With 24-Hour Hackathon

SPIC Rolls Our Strategic HR Initiatives for Better Organization Performance

P&G Reimagines Creativity to Reinvent Advertising Through Innovative New Creative Partnerships

Intuit’s QuickBooks Assistant Wins Asia-Pacific Stevie Award

CrowdStrike Appoints Inflow Technologies as Strategic APJ Distributor

RSA Conference 2019 Asia Pacific & Japan Unveils Keynote Stage Line-up

Global Upside’s HR Team and Mihi Software Honored at PeopleFirst HR Excellence Awards 2019

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Sonia Gandhi chairs meeting to chalk out...
Twitter suspends pro-Khalistan activist ...
Suspected IED defused near a school in M...
Senior police officer breaks down carryi...
AIIMS RDA calls off strike, insists on t...
Rajnath, Army Chief to pay homage to Arm...
More...    
 
 Top Stories
Agartala airport to be 3rd internat... 
Congress meets at Sonia's house to ... 
Qureshi, Pompeo discuss bilateral t... 
We don't want thieves in our party:... 
Calm your muscles at workplace with... 
Farmer attempted suicide before Mah... 
Owaisi replies 'Allahu Akbar' as MP... 
Centre will make all efforts to hel...